A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Official record

Identifier

NCT06820463

Recruiting locations

countries

United StatesAustraliaAustriaBrazilCanadaCzechiaFranceGreeceIsraelItalyJapanPuerto RicoSpainTaiwanUnited Kingdom

Interventions studied

Telisotuzumab AdizutecanFluorouracilOxaliplatinLeucovorinBevacizumabPanitumumab

Lead sponsor

AbbVie

Target enrolment

390 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Recruiting

First posted

Feb 11, 2025

Last updated on the registry

Sep 28, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Laboratory values meeting the criteria within the protocol.
* Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.

Exclusion Criteria:

* Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
* History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.

Indexed under

Colorectal Cancer